A woman in her seventies who was started on warfarin after heart valve replacement began outpatient adjuvant chemotherapy with tegafur-uracil/leucovorin for rectal cancer. The patient performed weekly INR self-measurements at a health insurance pharmacy between outpatient visits. Results recorded in her personal medicine notebook were shared between her physician, a hospital pharmacist, and a pharmacy phar- In this study, we implemented a collaborative outpatient medication management system for a patient who had concomitant administration of WF and a combination of a fluorouracil agent tegafur-uracil and leucovorin (UFT/LV). A health insurance pharmacy-based pharmacist assisted the patient to perform pointof-care testing (POCT) for INR self-measurement between outpatient visits. Information on appropriate WF doses deduced from the results of INR self-measurement, the situation regarding adverse effect, and medication status were shared between the health insurance pharmacy-based pharmacist, a hospital-based physician, and a hospital-based pharmacist. Herein, we report our implementation and outcomes of this system that aimed to provide appropriate WF therapy.
| INTRODUCTION
Enhancement of the anticoagulant action of warfarin (WF) by concomitant administration with a fluorouracil antitumor agent has been reported. However, the mechanisms and timing of their interaction remain unclear, and thus, regular blood coagulation tests are recommended to adjust WF dosing based on INR values while continuing anticancer treatment. [1] [2] [3] In this study, we implemented a collaborative outpatient medication management system for a patient who had concomitant administration of WF and a combination of a fluorouracil agent tegafur-uracil and leucovorin (UFT/LV). A health insurance pharmacy-based pharmacist assisted the patient to perform pointof-care testing (POCT) for INR self-measurement between outpatient visits. Information on appropriate WF doses deduced from the results of INR self-measurement, the situation regarding adverse effect, and medication status were shared between the health insurance pharmacy-based pharmacist, a hospital-based physician, and a hospital-based pharmacist. Herein, we report our implementation and outcomes of this system that aimed to provide appropriate WF therapy.
| CASE
A woman in her seventies had undergone artificial heart valve replacement for valvular disease complicated by atrial fibrillation in October year X. WF therapy (2.0 mg daily) was started after surgery.
Following an investigation into melena, rectal cancer was diag- positive, and thus, the risk of recurrence was expected to be high in accordance with the colorectal cancer treatment guidelines. After providing sufficient explanation and obtaining consent from the patient, outpatient adjuvant chemotherapy with UFT/LV (six cycles of a 35-day regimen: UFT 500 mg daily plus LV 75 mg daily for 28 days followed by a 7-day break) was started.
| Procedures of the collaborative outpatient medication management system
The procedure of the collaborative outpatient medication management system was established based on the outcomes of the meeting held between a hospital physician, a hospital-based pharmacist (hereinafter referred to as the hospital pharmacist), and a health insurance 
4.
Based on the information passed by the hospital pharmacist, the physician gave instruction (withholding or adjusted doses of WF) to the hospital pharmacist, who then called the pharmacy pharmacist to inform the physician's instruction.
5.
The pharmacy pharmacist instructed the patient according to the adjusted medication (withholding or alteration of WF doses).
| POCT for INR self-measurement
Point-of-care testing for INR self-measurement was performed by the patient using the CoaguChek® XS (EIDIA Co. Ltd, Tokyo, Japan).
Instructions on machine operation, disinfection of the site of needle insertion, and disposal of biohazardous waste (eg, blood contaminated needles) were given by the pharmacy pharmacist prior to self-measurement.
| Evaluation of the effect of WF therapy based on the time in the therapeutic range (TTR)
The TTR, which is the percent of time when INR was maintained within the therapeutic range, was used to evaluate the effect of WF therapy.
The TTR values during a 24-week period before and a 24-week period after the start of UFT/LV therapy were evaluated.
| Ethical considerations
This study was performed after obtaining approval from the Clinical Research Ethics Committee of the School of Pharmacy, Aichi Gakuin University. The TTR during the 24-week period before the concomitant administration of WF and UFT/LV was 94.0%, while that during the 24-week period after concomitant administration was 75.6%.
| Clinical course
There were no adverse effects during the combination treatment with WF and UFT/LV.
| DISCUSSION
A possible mechanism for increases in INR, which occur when WF is 
